Buy Jupiter Life Line Hospitals; target of Rs 1720: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Jupiter Life Line Hospitals has recommended buy rating on the stock with a target price of Rs 1720 in its research report dated May 13, 2025.

Broker Research

May 14, 2025 / 12:30 IST

buy

26 Aug, 2025 12:21

Volume

Todays L/H

Prabhudas Lilladher's research report on Jupiter Life Line Hospitals

JLHL’s Q4 consolidated EBITDA grew by 26% YoY (4% QoQ) to Rs783mn, largely in line with our estimates, aided by higher ARPOB. Its operational efficiency has been strong in the competitive markets of MMR. The company reported revenue/EBITDA CAGR of 20%/25% over FY22-25. Given its expansion plans, scale-up in occupancy and improving margins, growth momentum is expected to sustain over the medium term. We believe strategic greenfield expansions in densely populated micro-markets of western regions will drive sustainable growth. Our FY26E and FY27E EBITDA broadly remain unchanged, but PAT has been reduced by ~11% given the higher depreciation and interest charges.

Outlook

Overall, we see 20%/16% CAGR in EBITDA/PAT over FY25-27E with healthy return ratios of ~20%. Maintain ‘BUY’ rating with a revised TP of Rs1,720/share, valuing at 26x EV/EBITDA based on FY27E EBITDA.

For all recommendations report, click here